Accenture Invests in 1910 Genetics to Enhance Drug Discovery With AI
Accenture Ventures has invested in 1910 Genetics, a biotechnology firm specializing in AI-driven drug discovery for both small and large molecules. This collaboration is set to integrate Accenture's AI capabilities with 1910’s multimodal platform, aiming to streamline drug discovery and development, lower R&D costs, and increase therapeutic accessibility.
1910 Genetics leverages its proprietary Input-Transform-Output (ITO) platform—a scalable, end-to-end AI solution optimized for target identification, molecule design, and simulation across various therapeutic areas.
This multi-AI system incorporates hundreds of models, using federated learning and three proprietary data streams:
- Computational
- Wet Lab Ground Truth
- Wet Lab Proxy Biological Data
The platform is designed to facilitate data-driven decision-making, with the potential to increase clinical success probabilities, minimize experimental cycles, and reduce development costs.
See also: Companies Making Automated Drug Discovery a Reality
Accenture's expertise in scaling AI solutions across industries will support 1910's platform integration within existing biopharma pipelines. Petra Jantzer, Accenture’s global lead of Life Sciences, emphasized the potential to automate and enhance drug discovery processes by uniting Accenture’s enterprise-wide generative AI capabilities with 1910’s advanced infrastructure.
Jen Nwankwo, PhD, founder and CEO of 1910 Genetics, commented on the collaboration:
“In our discussions with biopharma companies, the desire for AI transformation of their traditional R&D processes is evident. It’s also clear that 1910’s end-to-end AI platform—from in silico to the wet lab and back—addresses the challenges that biopharma companies face with point solutions. By collaborating with Accenture, we aim to bring 1910’s AI platform to biopharma companies as an enterprise-wide horizontal infrastructure that breaks down barriers in data, model, and computing power to accelerate the discovery and development of both small and large molecule therapeutics across all therapeutic areas.”
The collaboration also includes Accenture Ventures' Project Spotlight, a program aimed at scaling disruptive technologies. Accenture executives Dr. Petra Jantzer, Tom Lounibos, Dr. Kailash Swarna, and Dr. Cecil Lynch will join advisory boards to support the joint initiative.
1910 Genetics, founded in 2021 with $26.1 million in funding from investors including M12 and Playground Global, operates from its headquarters in Boston’s Seaport District, focusing on neurology, autoimmune diseases, and cancer.
Topics: Startups & Deals
